← All trials
NCT04565054
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 2, 2020
- Primary completion
- Aug 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Sep 25, 2020
- Last posted
- Sep 25, 2020
- Enrollment
- 1250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- West German Study GroupLead sponsor
- Eli LillyCollaborator
- Genomic HealthCollaborator
- West German Study GroupOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.